← back to search

Silvya Stuchi Maria–Engler

Universidade de São Paulo · BR
Area of research
Molecular Biology · Cell Biology
Research interest
Research interests include Melanoma and MAPK Pathways, melanin and skin pigmentation, Skin Protection and Aging, and Protease and Inhibitor Mechanisms.
h-index
37
citations
4,605
works
219
NIH funding
primary concept
Chemistry
email

Recent publications

Exploiting Paradoxical Activation of Oncogenic MAPK Signaling by Targeting Mitochondria to Sensitize <i>NRAS</i> Mutant-Melanoma to Vemurafenib.
2025cited by 3position: contributordoi
Differential impacts of nickel toxicity: NiO and NiSO4 on skin health and barrier function
Ecotoxicology and Environmental Safety 2025cited by 2position: contributordoi
Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid.
2024cited by 204position: contributordoi
Evaluation of the photoprotective and antioxidant potential of an avobenzone derivative.
2024cited by 7position: contributordoi
Peroxiredoxin-2 represses NRAS-mutated melanoma cells invasion by modulating EMT markers.
2024cited by 7position: contributordoi
Modeling Melanoma Heterogeneity In Vitro: Redox, Resistance and Pigmentation Profiles.
2024cited by 3position: contributordoi
MITF, TFEB and TFE3 drive distinct adaptive gene expression programs and immune infiltration in melanoma
2024cited by 2position: contributordoi
Brazilian National Network of Alternative Methods (RENAMA) 10th Anniversary: Meeting of the Associated Laboratories, May 2022.
2024cited by 1position: contributordoi
Tissue Engineering Challenges for Cultivated Meat to Meet the Real Demand of a Global Market.
2023cited by 15position: contributordoi
Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma.
2023cited by 12position: contributordoi
2-Methoxyestradiol-3,17-O,O-bis-sulfamate (STX140) Inhibits Proliferation and Invasion via Senescence Pathway Induction in Human BRAFi-Resistant Melanoma Cells
International Journal of Molecular Sciences 2023cited by 1position: contributordoi
Epidermal melanocytes metabolize extracellular nucleotides by purinergic enzymes.
2023cited by 0position: contributordoi
Redox-Related Proteins in Melanoma Progression.
2022cited by 21position: contributordoi
Kynurenine inhibits melanogenesis in human melanocyte-keratinocyte co-cultures and in a reconstructed 3D skin model.
2022cited by 9position: contributordoi
Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma.
2022cited by 9position: contributordoi
<i>Pouteria macrophylla</i> Fruit Extract Microemulsion for Cutaneous Depigmentation: Evaluation Using a 3D Pigmented Skin Model.
2022cited by 7position: contributordoi
Mesenchymal stem cells express epidermal markers in an <i>in vitro</i> reconstructed human skin model.
2022cited by 5position: contributordoi
3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells.
2022cited by 5position: contributordoi
Quercetin increases mitochondrial proteins (VDAC and SDH) and downmodulates AXL and PIM-1 tyrosine kinase receptors in NRAS melanoma cells.
2022cited by 3position: contributordoi
Glutamic acid promotes hair growth in mice.
2021cited by 19position: contributordoi
Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn's Disease.
2021cited by 15position: contributordoi
Immunotoxic mechanisms of cigarette smoke and heat-not-burn tobacco vapor on Jurkat T cell functions.
2021cited by 13position: contributordoi
In Vitro Evaluation of the Photoprotective Potential of Quinolinic Alkaloids Isolated from the Antarctic Marine Fungus Penicillium echinulatum for Topical Use.
2021cited by 11position: contributordoi
Nanostructured lipid carriers enhances the safety profile of tretinoin: <i>in vitro</i> and healthy human volunteers' studies.
2021cited by 6position: contributordoi
Anhydroecgonine methyl ester, a cocaine pyrolysis product, contributes to cocaine-induced rat primary hippocampal neuronal death in a synergistic and time-dependent manner.
2021cited by 5position: contributordoi
Skin Equivalent Models: Protocols for In Vitro Reconstruction for Dermal Toxicity Evaluation.
2021cited by 4position: contributordoi
Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy.
2020cited by 33position: contributordoi
Fucoxanthin for Topical Administration, a Phototoxic vs. Photoprotective Potential in a Tiered Strategy Assessed by In Vitro Methods.
2020cited by 29position: contributordoi
Air Particulate Matter Induces Skin Barrier Dysfunction and Water Transport Alteration on a Reconstructed Human Epidermis Model.
2020cited by 29position: contributordoi
Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics.
2020cited by 25position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 18 papers (2019–2025)Larissa Anastasio Da Costa Carvalho · Moffitt Cancer Center3 papers (2020–2022)Wilson Araujo Silva · Universidade Federal da Paraíba3 papers (2022–2024)Erica Oliveira · Institute of Cancer Research3 papers (2020–2025)Marcelo G. Bonini · Moffitt Cancer Center2 papers (2014–2014)Márcia Edilaine Lopes Consolaro · University of Illinois Chicago2 papers (2014–2014)Fabrícia Gimenes · University of Illinois Chicago2 papers (2014–2014)André Luelsdorf Pimenta de Abreu · University of Illinois Chicago2 papers (2014–2014)Hosana Maria Debonsi · Universidade de São Paulo Faculdade de Ciências Farmacêuticas de Ribeirão Preto2 papers (2020–2020)Renata Spagolla Napoleão Tavares · Brazilian Center for Research in Energy and Materials2 papers (2020–2020)Tiago Rodrigues · Universidade Federal do ABC2 papers (2022–2025) · 1 papers (2014–2014) · 1 papers (2020–2020)Y. Ann Chen · Zhejiang Chinese Medical University1 papers (2019–2019) · 1 papers (2019–2019)Lesley de Armas · University of Miami1 papers (2019–2019)Jane L. Messina · Moffitt Cancer Center1 papers (2019–2019) · 1 papers (2020–2020)Pep Amengual-Rigo · Sanofi (France)1 papers (2020–2020) · 1 papers (2014–2014)